Home / Resource Library / Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First Line Therapy in Patients with High Risk Large B-Cell Lymphoma (LBCL)

Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First Line Therapy in Patients with High Risk Large B-Cell Lymphoma (LBCL)

ASH 2021

Membership Organisation

Healthcare Professional

Affected by Lymphoma

Researcher or Advocate

Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First Line Therapy in Patients with High Risk Large B-Cell Lymphoma (LBCL)